Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 3
1993 2
1994 1
1995 2
1996 3
1997 1
1998 3
1999 1
2000 1
2001 2
2002 1
2003 3
2005 1
2006 3
2007 4
2008 7
2009 3
2010 1
2012 1
2013 2
2014 5
2015 10
2016 8
2017 11
2018 10
2019 6
2020 2
2021 6
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30513755

98 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Harris PNA, et al. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. JAMA. 2018. PMID: 30208454 Free PMC article. Clinical Trial.
Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types.
Edwards T, Heinz E, van Aartsen J, Howard A, Roberts P, Corless C, Fraser AJ, Williams CT, Bulgasim I, Cuevas LE, Parry CM, Roberts AP, Adams ER, Mason J, Hubbard ATM. Edwards T, et al. Microb Genom. 2022 Apr;8(4):000789. doi: 10.1099/mgen.0.000789. Microb Genom. 2022. PMID: 35404783 Free PMC article.
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. Harris PN, et al. Trials. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9. Trials. 2015. PMID: 25623485 Free PMC article. Clinical Trial.
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A. López-Cerero L, et al. Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15. Clin Microbiol Infect. 2010. PMID: 19614715 Free article.
Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM, Tomé G, Bantar C, Bertolini P, Blázquez N, Borda N, Couto E, Cudmani N, Guerrera J, Juárez MJ, López T, Littvik A, Méndez E, Notario R, Ponce G, Quinteros M, Salamone F, Sparo M, Sutich E, Vaylet S, Wolff L. Casellas JM, et al. Diagn Microbiol Infect Dis. 2003 Nov;47(3):527-37. doi: 10.1016/s0732-8893(03)00131-7. Diagn Microbiol Infect Dis. 2003. PMID: 14596972
98 results